ClinicalTrials.gg
CompletedNCT06765720Updated Nov 5, 2026

Effects of Intermittent Feeding Methods With Nasogastric and Orogastric Tubes in Preterm Infants

An interventional study of Intermittent feeding method with nasogastric tube and Intermittent feeding method with orogastric tube in Nasogastric Tube and Orogastric Tube, sponsored by İstanbul Yeni Yüzyıl Üniversitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 30 Weeks to 36 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by İstanbul Yeni Yüzyıl Üniversitesi · Not applicable, Interventional, and Health services research

How we know

Updated Nov 5, 2026Now CompletedFirst site in Turkey (Türkiye)+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Weeks to 36 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.

Enrollment
105th of 197
60 · median 64
Started
2025
with 21 others
No phase
192 of 247
39 open now
Registered
184th of 247
by date

Among the 247 studies in Premature Birth with a site in Turkey, this one is the 105th largest by enrollment of the 197 interventional ones that give a count, is one of 22 that started in 2025, is one of 192 with no phase, and was the 184th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 30 Weeks to 36 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Premature Birth with a site in Turkey, or all of them as a file.
02

Study summary

The study is a randomized controlled, prospective, double-blind trial planned to compare the effects of intermittent feeding methods using nasogastric and orogastric tubes on the growth, nutrition, and physiological parameters of preterm infants.

The population of the study will consist of preterm infants admitted to the Neonatal Intensive Care Unit of a public hospital in Istanbul between February and December 2025. The sample will include 60 preterm infants who meet the research criteria and whose parents agree to participate in the study.

Through randomization, preterm infants will be assigned to either the nasogastric tube group (experimental) or the orogastric tube group (control) from their first enteral feeding until the transition to full oral feeding is completed.

Data for preterm infants in both groups will be collected using the "Preterm Infant Information Form, Early Feeding Skills Assessment Tool, and Nutrition Monitoring Form," which were developed by the researchers based on literature information and expert opinions. These data will encompass growth, nutrition, and physiological parameters before, during, and after feeding throughout the study.

Hypotheses of the Study

H0: There is no significant difference in the effects of intermittent feeding methods using nasogastric and orogastric tubes on growth, feeding complications, and physiological parameters in preterm infants.

H1: There is a significant difference between intermittent feeding methods using nasogastric and orogastric tubes in preterm infants in terms of growth parameters (daily weight gain in grams, time to regain birth weight, time to transition to full enteral feeding, time to transition to full oral feeding, and Early Feeding Skills Assessment Tool score).

H1(1): Preterm infants fed with a nasogastric tube have greater daily weight gain (grams) compared to those fed with an orogastric tube.

H1(2): The time to regain birth weight (days) in preterm infants fed with a nasogastric tube is shorter compared to those fed with an orogastric tube.

H1(3): The time to transition to full enteral feeding (days) in preterm infants fed with a nasogastric tube is shorter compared to those fed with an orogastric tube.

H1(4): The time to transition to full oral feeding (days) in preterm infants fed with a nasogastric tube is shorter compared to those fed with an orogastric tube.

H1(5): The Early Feeding Skills Assessment Tool score of preterm infants fed with a nasogastric tube is higher compared to those fed with an orogastric tube.

H2: There is a significant difference between intermittent feeding methods using nasogastric and orogastric tubes in preterm infants in terms of feeding complications (tube replacement, mucosal trauma, and feeding intolerance).

H2(1): The frequency of tube replacement in preterm infants fed with a nasogastric tube is lower compared to those fed with an orogastric tube.

H2(2): The incidence of mucosal trauma in preterm infants fed with a nasogastric tube is lower compared to those fed with an orogastric tube.

H2(3): The incidence of feeding intolerance in preterm infants fed with a nasogastric tube is lower compared to those fed with an orogastric tube.

H3: There is a significant difference between intermittent feeding methods using nasogastric and orogastric tubes in preterm infants in terms of physiological parameters (oxygen saturation, heart rate, and apnea).

H3(1): The oxygen saturation levels during and after feeding in preterm infants fed with a nasogastric tube are higher compared to those fed with an orogastric tube.

H3(2): The heart rate during and after feeding in preterm infants fed with a nasogastric tube is lower compared to those fed with an orogastric tube.

H3(3): The incidence of apnea in preterm infants fed with a nasogastric tube is lower compared to those fed with an orogastric tube.

Read the detailed description

Enteral feeding is preferred as a safe method for preterm infants whose oral feeding skills have not yet developed or who are not ready for oral feeding. It is also implemented to support intestinal development and avoid the long-term side effects of parenteral nutrition. Enteral feeding is a method that allows infants to receive nutrients by utilizing the natural functions of their gastrointestinal system through the advancement of a feeding tube from the mouth or nose to the stomach. Feeding via nasogastric and orogastric tube methods, commonly used in neonatal intensive care units, provides enteral nutrition support for preterm infants. The nasogastric tube is inserted through the nose into the stomach, while the orogastric tube is placed through the mouth into the stomach. Both feeding methods offer various advantages and disadvantages based on the individual needs and clinical conditions of the infants. Therefore, the selection of the feeding method should involve a comprehensive evaluation of the potential benefits and risks unique to each method for the infant.

Since preterm infants breathe nasally, feeding with a nasogastric tube can cause partial nasal obstruction, leading to increased airway resistance and respiratory workload. This situation may result in the collapse of the pharyngeal airways and an increased incidence of apnea of prematurity in preterm infants. Additionally, prolonged feeding with a nasogastric tube in preterm infants has been reported to cause nasal septum defects. In contrast, while the placement and fixation of orogastric tubes are generally easier, these tubes can lead to complications such as displacement or incorrect placement into the lungs, aspiration, increased respiratory resistance, and bradycardia episodes due to vagal stimulation. Furthermore, the prolonged use of orogastric tubes in very low birth weight preterm infants may increase the risk of palate deformation. Therefore, the selection of the feeding method should be based on the infant's health status, respiratory functions, and other clinical parameters.

In the literature, studies investigating the effects of nasogastric and orogastric tubes on preterm infants have shown that the sample groups are limited, crossover designs were used, and there are methodological limitations regarding the determination of evaluation parameters and the process of transition to full enteral feeding. It has been observed that there is a need for a randomized controlled study with a large sample size to examine the effects of intermittent feeding methods using nasogastric and orogastric tubes on the growth, nutrition, and physiological parameters of preterm infants. Accordingly, this research was planned as a randomized controlled, prospective, double-blind study to compare the effects of intermittent feeding methods using nasogastric and orogastric tubes on the growth, nutrition, and physiological parameters of preterm infants.

The infants to be included in the study will be selected according to the determined inclusion criteria and then randomly divided into two groups: nasogastric tube feeding group and orogastric tube feeding group.

In the study, the randomization process will be carried out using the urn method. The urn method is equivalent to complete randomization and will be expressed with two parameters, α and β. These parameters will be symbolized as balls in red and white colors. White or red color will represent α; β will represent the opposite color of α. In each assignment process, the color of a randomly selected ball will determine which group the infant will be assigned to: when a white ball is selected, the infant will be assigned to the orogastric group, and when a red ball is selected, the infant will be assigned to the nazogastric group. In the study, the white ball will be designated as the orogastric group, and the red ball will be designated as the nazogastric group. For each new infant participant who meets the sample criteria, the previously prepared balls will be stored in a black bag, and a nurse on duty in the unit will randomly select one with their eyes closed. Based on the color of the selected ball, infants will be assigned to the groups, ensuring a random distribution between groups

03

Conditions studied

  • Nasogastric Tube
  • Orogastric Tube

Browse trials for

Keywords

  • intermittent feeding
  • enteral feeding
  • nasogastric tube
  • orogastric tube
  • preterm
04

Who can participate

Ages eligible
30 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants with a gestational age of ≥30 weeks at birth, determined according to the mother's last menstrual period, and appropriate for gestational age,
  • Postmenstrual age of ≥30 weeks at the time of inclusion in the study,
  • Recommended for enteral feeding by a neonatologist,
  • Infants starting enteral feeding for the first time and fed at three-hour intervals using gravity-assisted nasogastric or orogastric tubes,
  • Infants who have not undergone oral feeding trials,
  • Infants who have not received any oral motor interventions,
  • Infants whose parents have given consent for inclusion in the study and signed an form after being provided with detailed information.

Exclusion criteria

Exclusion Criteria:

  • Infants receiving mechanical ventilation support during the study,
  • Infants with an umbilical catheter,
  • Infants who received intubation, CPAP, or nasal prong oxygen support for more than 14 days before inclusion in the study,
  • Infants with craniofacial anomalies such as cleft palate, cleft lip, or facial muscle paralysis,
  • Infants with any gastrointestinal, neurological, or chromosomal disease (e.g., necrotizing enterocolitis, grade III and IV intracranial hemorrhage, periventricular leukomalacia, hydrocephalus, Down syndrome, and other diseases),
  • Infants with severe bronchopulmonary dysplasia according to the criteria of Jobe and Bancalari (2001) or requiring surgical treatment for patent ductus arteriosus.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Intermittent feeding method with nasogastric tube

    Preterm infants in this group will be fed via a nasogastric tube during the transition period from the initiation of enteral feeding to full oral feeding.

    Other: Intermittent feeding method with nasogastric tube

  • Experimental
    Intermittent feeding method with orogastric tube

    Preterm infants in this group will be fed via a orogastric tube during the transition period from the initiation of enteral feeding to full oral feeding.

    Other: Intermittent feeding method with orogastric tube

Interventions

  • OtherIntermittent feeding method with nasogastric tube

    30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding. 5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding. Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding. Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool.

  • OtherIntermittent feeding method with orogastric tube

    30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding. 5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding. Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding. Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool.

06

What researchers measure

Primary outcomes

  1. Time to transition to full enteral feeding

    An infant will be considered to have transitioned to full enteral feeding once all energy and nutrient needs are met for 48 hours through intermittent enteral feeding eight times a day at three-hour intervals.

    Time frame: From the infant's birth until the time they achieve full enteral feeding.Time frame is through study completion, an average of 8 months.

  2. Time to transition to full oral feeding

    An infant will be considered to have achieved full oral feeding once they can take 8 feedings per day orally at three-hour intervals for 48 hours and gain 20-30 g/kg.

    Time frame: From the infant's birth until the time they achieve full oral feeding.Time frame is through study completion, an average of 8 months.

  3. Time to regain birth weight

    Time frame: The number of days it takes for them to recover the weight they lost after birth.Time frame is through study completion, an average of 8 months.

  4. Daily weight gain

    Time frame: It will be measured every day throughout the research. Time frame is through study completion, an average of 8 months.

  5. Early Feeding Skills Assessment Tool score

    Time frame: It will be evaluated every day throughout the research.Time frame is through study completion, an average of 8 months.

Secondary outcomes

  1. Frequency of tube changes

    Time frame: It will be evaluated every day throughout the research.Time frame is through study completion, an average of 8 months.

  2. Incidence of mucosal trauma

    Time frame: It will be evaluated every day throughout the research.Time frame is through study completion, an average of 8 months.

  3. Development and frequency of feeding intolerance

    Time frame: Time frame is through study completion, an average of 8 months.

  4. Oxygen saturation levels

    Time frame: Time frame is through study completion, an average of 8 months.

  5. Heart rate variability

    Time frame: Time frame is through study completion, an average of 8 months.

  6. Incidence of apnea

    Time frame: Time frame is through study completion, an average of 8 months.

07

Study locations

1 site
  • Yeni Yüzyıl University
    Zeytinburnu, Istanbul 34010, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jul 2025, 4 months.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 4 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Feb 2025 → Mar 2025, primary completion Aug 2025 → Jul 2025 and completion Dec 2025 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 9, 2025
StartActual
Mar 1, 2025was Feb 2025
Primary completionActual
Jul 1, 2025was Aug 2025
CompletionActual
Nov 1, 2025was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 5, 2026
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Yeni Yüzyıl University · Zeytinburnu, Turkey (Türkiye)
Show 1 removed
  • Yeni Yüzyıl University · Zeytinburnu, Turkey
Nov 5, 2026
Start date
Feb 1, 2025→Mar 1, 2025 (actual)
Nov 5, 2026
Primary completion
Aug 1, 2025→Jul 1, 2025 (actual)
Nov 5, 2026
Study completion
Dec 1, 2025→Nov 1, 2025 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Yeni Yüzyıl University · Zeytinburnu, Turkey (Türkiye)
    Show 1 removed
    • Yeni Yüzyıl University · Zeytinburnu, Turkey
    Start date Feb 1, 2025→Mar 1, 2025 (now actual)
    Primary completion Aug 1, 2025→Jul 1, 2025 (now actual)
    Study completion Dec 1, 2025→Nov 1, 2025 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06765720
Lead sponsor
İstanbul Yeni Yüzyıl Üniversitesi
Responsible party
Fatma Çarıkçı (Lecturer, İstanbul Yeni Yüzyıl Üniversitesi) — Principal investigator
First posted
Jan 9, 2025
Start date
Mar 1, 2025
Primary completion
Jul 1, 2025
Completion
Nov 1, 2025
Last update
Nov 5, 2026

Study contacts

Burcu Aykanat Girgin, Assoc. Dr.
study director · Saglik Bilimleri Universitesi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion